Medtronic Inc. (MDT)

[TREND1]

MDT CORR

http://schrts.co/dDBSCs

[TREND1]

MDT ONE MONTH

http://schrts.co/xuvY9a

[TREND1]

PE-42.30

[TREND1]

EPS= $ 2.29

[TREND1]

MDT MONTHLY


http://schrts.co/hMr5oi

[TREND1]

MDT 7 YEARS

https://ih.advfn.com/p.php?pid=staticchart&s=NY%5EMDT&t=37&p=9&dm=0&vol=0&width=670&height=600&min_pre=0&min_after=0

[PennyStock Alert]

Taking a tiny dip, no issues :)

[KOGT]

Thanks phaeton. Bookmrked

[Phaeton]

Below is an article from a website today talking about the benefits of the partnership between MDT & Mazor Robotics.

Read the article about Mazor.

Great article on why this company has a lot of room to run with $MDT as a partner.

https://www.medtechy.com/the-ticker/articles/2017/medtronic-and-mazor-robotics-need-each-other

Excerpt:
The $72 million invested by Medtronic (as of Sept 2017) has allowed Mazor to scale at a much faster rate then they ever would have without the capital.

Excerpt:
Medtronic also has warrants allowing them to buy another 1.2 million shares, which could bring their total investment to $125 million, or 14% ownership of the company.

Excerpt:
It's Not Just About the Money
It's not just the capital though, Mazor could get funding from anyone. What they received with Medtronic's money is an instant world-class sales organization that provides contacts and validation in the U.S.

Trust me, getting a product launched in the U.S. without a sales team, marketing and validation is virtually impossible.

This partnership is a win-win for both companies.

They are two companies that need each other. Mazor doesn't have the sales infrastructure in place and Medtornic's Spine division is a mess.

[ITMS]

Medtronic PLC (NYSE:MDT) Technical Outlook

Leading medical device manufacturer Medtronic PLC (NYSE:MDT) has been under selling pressure since June 26th, 2017. At that time, the stock traded as high as $89.72 a share before topping out. Today, MDT stock is trading around $78.00 a share and should still have a bit more downside in the near term. Traders and investors should now watch the $74.50 level as the next major chart support area. This support level matches up nicely with the weekly 200 period moving average. It is also important to note that this area was where the stock was defended in January 2017.



Nicholas Santiago
InTheMoneyStocks

[Phaeton]

New SEC filing that is good for Mazor. It is a SEC form 13G that shows that Medtronic (MDT) now owns 16% of Mazor. This is the next phase of their agreement. This is good for shareholders. Added stability.


http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=12283145&RcvdDate=9/15/2017&CoName=MAZOR%20ROBOTICS%20LTD.&FormType=SC%2013G/A&View=html

[pranjal]

Medtronic is in the list of top companies in Spine Surgery Devices!

view more

[stealthways]

Medtronic has a chance to leapfrog into the top of the orthopaedic implant business. Zimmer Biomet is by all accounts planning to make an acquisition of Amedica. Medtronic could, by moving swiftly, buy Amedica first. This would give Medtronic a strong competitive advantage. Amedica tech includes new generation of sini with worldwide patents, 3-D printing, anti-infective properties, and approval on the horizon for many products and markets... Lets see Medtronic be a tech leader.... buy Amedica

[stocktrademan]

MDT buy option 84.06

buy 26 MAY 16 85 call for 0.76









normal chart




log chart

[TREND1]

3/21 A live audio webcast of the presentation will be available on March 21, 2017, by clicking on the Investor Events link at http://investorrelations.medtronic.com. An archive of the session will be available on the same webpage later in the day.

[TREND1]

MDT DAILY

[TREND1]

MDT DAILY

[TREND1]

MDT DALY

[TREND1]

MDT DAILY

[TREND1]

About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 88,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

[TREND1]

DIV=US$ 1.72

[TREND1]

EPS = 1.51

[TREND1]

MKT CAP= 108.31B

[TREND1]

MDT DAILY WEEKLY CHANNELS

[ValueInvestor15]

Our Medtronic $MDT fundamental analysis highlights stock's 8% undervalued b4 earnings Tuesday:

Fair Value Source

[trendmkr]

Medtronic Plc. (NYSE:MDT) Launches New Tools In Coronary Portfolio
https://marketexclusive.com/medtronic-launches-new-tools-in-coronary-portfolio/72284/?icd1

[TattooedTraderFry]

Question does this company make insulin pumps for diabetes

[Mr_Doug]

Flat for the day but I'm seeing all this buying after hours? I'm a little surprised considering the mood of the market today.

[ValueInvestor15]

Thanks. Evercore reiterated its Buy rating for Medtronic today along with an $80 price target... Rating Change

[Twister]

Nice call...

[FutureBankruptcy]

whats your take on the big gap down today?

[ValueInvestor15]

MDT trading at a 12% discount to Fair Value before earnings:

FAIR VALUE

[Pocket9s]

Time to bid 50$

[PStockPickz]

news out

[Hypocrates]

Medtronic has the cash, but Titan has the product. Get it while it is cheap!

[TREND1]

About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 85,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together

[TREND1]

FLOAT = 1.41 BILLION

[TREND1]

EPS = 2.51

[TREND1]

***** 6/30/16 As promised, Medtronic ($MDT) has filed for premarket approval for its hybrid closed-loop system, which measures diabetics' blood glucose levels in real time and automatically adjusts the amount of insulin it delivers.

Medtronic anticipates approval in the spring next year. If approved, it will be the world's first "artificial pancreas." The system comprises Medtronic's MiniMed 670G insulin pump, fourth-generation glucose monitors and a control algorithm. The sensors are worn for 7 days before they need recharging, while the insulin pump needs to be refilled every three days, Bloomberg reported.

The submission is based on pivotal data, which Medtronic presented to the American Diabetes Association conference earlier this month. The data showed that the system helped to lower A1c levels and maintain more consistent blood glucose sensor values in 124 patients with Type 1 diabetes. No adverse events were reported in the study, which spanned 12,389 patient days. At the end of the study, most of the patients chose to join the continued-access program for the device.

A separate study involving 12 adults and 16 adolescents showed that overnight use of the closed-loop system reduced the time adults needed to get to their target glucose range and decreased nocturnal hypoglycemia for the adolescents.

Medtronic is leading the race to get an artificial pancreas to market, but the device giant isn't stopping there. It is working on a fully closed-loop system using its new Harmony 1 sensor, which is expected to last 10 days. The company also expects it to be more accurate and require just one calibrating finger-stick a day, rather than the twice-daily requirement of most continuous glucose monitors.

The artificial pancreas could ramp up Medtronic's diabetes business, which booked $496 million in revenues in the most recent quarter, which ended May 31. The Diabetes Group accounted for 7% of the company's business and grew 10% last year, with insulin pump sales growing 30% outside the U.S. The company will accelerate in diabetes, with plans to roll out "more new products in the next 5 years than we have in the last 15 years," said Diabetes Group President Hooman Hakami at an investor day earlier this year.

[TREND1]

MDT DAY

[BudFoxWallStreet]

Medtronic joined the most recent round for this company. EarLens has a strong product and management team. Could be an acquisition target.

https://www.medtechy.com/the-ticker/articles/2016/earlens-raises-another-51m

[was CUIN2]

Intuitive Surgical has been the leader in the surgical robotic market for the past 15 years, but two new surgical robotic systems are expected to come to the market this year. Those systems are Titan Medical’s SPORT system, which is for general abdominal, gynecologic, urologic and colorectal procedures, and TransEnterix’s SurgiBot robotic system, which doesn’t have any known indications yet.

https://m.dotmed.com/news/story/29980

[Goldmind]

If this trend continues, i will be up 7 pct by Friday:)

[Goldmind]

Up 4 percent:)

[TREND1]

MARKET CAP/REVENUE = 5.1

[justiniano]

MDT is working with MC 10 look it up.

[Stock Trading Guru]

Medtronic has some killer diabetes tech hitting markets. Also, thanks to ObamaCare there is expanding insurance coverage for Medtronic's devices.

Check out the new Medtronic's diabetes tech Diabetes Technology Inches Closer To An Artificial Pancreas

[$Pistol Pete$]

Medtronic should buy out NVLX

http://www.accessdata.fda.gov/scripts/opdlisting/oopd/oopd_results_2.cfm?index_number=457014

[maytepper]

$MDT Oppenheimer Raises Medtronic Price Target Following Fiscal 2Q15 Earnings http://www.smarteranalyst.com/2014/11/19/oppenheimer-raises-medtronic-price-target-following-fiscal-2q15-earnings/

[investora2z]

The last quarter earnings for Medtronics added some strength to the stock. Compared with a correction of more than 10% in most stocks, it has remained relatively stable over the past few weeks. It is only 4% below its 52 week high of $53.83 made a few days ago. It is trading above important levels, and sustained improvement in the mood of the market can help it challenge recent highs. The full year guidance of 2014 was raised to $17.1-17.3 billion which indicates expectations of 3% growth. In the last quarter, the company reported revenues & net income of $4.46 billion and $969 million respectively. For the full fiscal year ending April 26, 2013, it reported revenues of $16.59 billion and net income of $3.467 billion. Going by the guidance, the growth in stock is likely to be modest over the next few quarters. Further, the markets have to remain stable to positive. Deeper correction in the market may dampen the overall sentiments and even strong stocks may give way. Medtronic has done well over the years for investors, and the growth in the stock has been backed by fundamentals. However, there was some slowing of growth in the last year. It is trading at around 15 times ttm earnings and the forward P/E is only slightly lower at 12.5. This again indicates that growth expectations are not that robust. Growth in revenues has always been supported by launch of innovative products by the company. Innovation is the key for success in the sector and even smaller medical device companies like PLC Systems (PLCSF) are showing promise based on innovative products. Majority of sales of Medtronics come from US and Europe, but emerging markets are also expected to contribute more in the years to come. Emerging markets was the fastest growing region for the company with 21% growth in revenues in 2012.